Article Details

Affimed Presents Findings from the Dose-escalation Phase of the First-in-human Study of ...

Retrieved on: 2022-04-09 23:40:36

Tags for this article:

Click the tags to see associated articles and topics

Affimed Presents Findings from the Dose-escalation Phase of the First-in-human Study of .... View article details on HISWAI: https://pipelinereview.com/index.php/2022040980643/Antibodies/Affimed-Presents-Findings-from-the-Dose-escalation-Phase-of-the-First-in-human-Study-of-AFM24-in-Patients-with-EGFR-positive-Solid-Tumors.html

Excerpt

Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company ... PipelineReview.com is powered by La Merie Business Intelligence La Merie ...

Article found on: pipelinereview.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up